NeuroPortal™ TfR1-Mediated Blood-Brain Barrier Drug Delivery Platform
An affinity-tunable TfR1-targeting VHH binders designed to support delivery of diverse therapeutic biologics cross the blood–brain barrier (BBB).

CNS Drug Delivery Engineered Around Your Molecule

Unlock CNS access
Leverage receptor-mediated transport through endogenous transferrin receptor (TfR1) biology to support delivery of biologics across the BBB.

Precision through affinity tuning
Evaluate TfR1-binding affinity profiles to explore the balance between receptor engagement, BBB transport and brain exposure.

Built for flexibility
Explore genetic fusion and bioconjugation approaches across relevant therapeutic formats.

Expert development support
Leverage Lonza expertise in protein expression, bioconjugation and developability.
Unlock your BBB transport with NeuroPortal™ TfR1 Technology
NeuroPortal™ TfR1-binding single-domain antibodies (VHHs) are designed to support receptor-mediated transport of biologics across the blood–brain barrier.
Three main approaches facilitate a robust drug design and discovery space
Genetic fusion
TfR1-binding VHHs can be incorporated into the molecular design of a new antibody or protein therapeutic.

Bioconjugation
TfR1-binding VHHs can be attached to an existing antibody without the need for antibody re-engineering.

Fusion plus bioconjugation
A genetically fused BBB transporter can be combined with a conjugated payload.

Scientific poster
Affinity Optimization of Anti-TfR1 VHH Blood-Brain Barrier Crossers for CNS Delivery Applications
Optimization of transferrin receptor engagement is critical for achieving efficient receptor-mediated transport across the blood-brain barrier. We investigated anti-TfR1 VHH shuttle variants spanning a range of binding affinities in bispecific antibody formats and evaluated their transport characteristics in a human BBB model. Comparative analysis revealed affinity-dependent differences in transcytosis performance, providing mechanistic insight into BBB shuttle design and supporting the development of next-generation CNS delivery strategies for biologics and bioconjugates.

Precision through affinity tuning
Stronger receptor binding does not necessarily mean greater brain exposure. NeuroPortal™ TfR1 technology offers VHH variants with different binding affinities so developers can evaluate which profile best suits their molecule and delivery objectives. This allows you to identify the optimal balance between receptor engagement, BBB transport, and brain exposure for their therapeutic and delivery objectives.
A tailored approach for your CNS program
Every CNS program has unique delivery requirements. Lonza’s structured evaluation packages provide a fast and flexible way to assess genetic fusion, bioconjugation, and combined approaches with your drug candidate, helping you identify the optimal path forward for BBB transport and brain exposure.
Different affinity profiles. Optimized therapeutic delivery.
Come to us with your CNS delivery challenge
Discuss your ideas, available antibodies, target and CNS delivery objectives with our experts to explore an appropriate evaluation approach.
Contact our technical experts to learn more